Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Active not recruiting 1

Sponsor Class

NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 3Gynecologic 2Gastrointestinal 2Tumor-Agnostic 1Thoracic 1Other hematologic neoplasm 1Myeloid 1Genitourinary 1

Conditions

Neoplasm Metastasis 1

Interventions

pembrolizumab 55Specimen Handling 28Biopsy 28Magnetic Resonance Spectroscopy 26Paclitaxel 23Blood Specimen Collection 22Nivolumab 20atezolizumab 18Standard of Care 18Carboplatin 18Surveys and Questionnaires 17Bevacizumab 17Oxaliplatin 13Fluorouracil 13Cisplatin 13Radiotherapy 12Radiosurgery 12Cyclophosphamide 12Pemetrexed 11Leucovorin 11Irinotecan 10Gemcitabine 10Docetaxel 10Capecitabine 10trastuzumab deruxtecan 8olaparib 8durvalumab 8Taxes 8Ipilimumab 8Trastuzumab 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Genetic Profile × Tumor-Agnostic × 1 year × Clear all
NCT05455606 2026-01-22

Does the Use of a Genomic Tumor Board Increase the Number of Patients Who Receive Genome-Informed Treatment

SWOG Cancer Research Network

Phase NA Active not recruiting
1,284 enrolled
Tumor-Agnostic

Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡